Keros Therapeutics (KROS) Director Bienaime Buys 1,000 Shares

What Happened
Bienaime Jean Jacques, a director of Keros Therapeutics (KROS), purchased 1,000 shares on July 15, 2026. The reported weighted-average price was $10.61 per share, for a total reported cost of $10,610. The filing shows a purchase (code P), which is a direct buy of common stock rather than a sale or option exercise.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-17 (no indication of a late filing).
• Price: weighted average $10.61; actual trade prices ranged from $10.46 to $10.80 (multiple trades).
• Total purchased: 1,000 shares; total reported value: $10,610.
• Ownership after transaction: not provided in the summary data supplied.
• Notable footnotes: (F1) shares were acquired pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025; (F2) price is a weighted average across multiple transactions and the insider can provide the per-trade breakdown on request.

Context
Purchases reported under a 10b5-1 plan are pre-scheduled trading arrangements and are considered routine insider buying; they are factual disclosures rather than commentary on near-term company prospects. For retail investors, insider purchases can be informative, but this single small purchase ($10.6k) should be weighed with other insider activity and company fundamentals.